Please assess the completion status of the following clinical trial:

Trial Title: Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females with a confirmed genetic diagnosis of Prader-Willi syndrome~2. Age:~   1. Step 1: Adults aged 18-30~  2. Step 2: Adolescents aged 12-17~3. Body Mass Index (BMI):~   1. Step 1: Adults with ≥25 kg/m2~  2. Step 2: Children with a BMI \>85th percentile for the same age and sex~4. Normal Blood Pressure (BP) or well managed hypertension (only if dose of BP medication(s) has been stable for \>2 months)~5. Normal lipid profile or well managed dyslipidemia (only if dose of lipid-lowering medication(s) has been stable for \>2 months)~6. Growth hormone is allowed; but patient must be on stable dose of growth hormone \>2 months~7. Type 2 diabetes is allowed, but the following criteria must be met:~   1. HbA1c \<10.0 % not being managed with insulin within the past 3 months~  2. Patients taking GLP-1 analogues (e.g. exenatide, liraglutide) must have been on stable dose for \>3 months~  3. Fasting plasma glucose \<11.0 mmol/l~Exclusion Criteria:~1. BP:~   1. Step 1: Adults with \>140/90~  2. Step 2: Adolescents with ≥95th percentile for gender, age, and height~2. Heart Rate (HR) ≥ 90, \<50 bpm~3. Hypersensitivity to tesofensine/metoprolol~4. Type 1 diabetes~5. Heart failure New York Heart Association (NYHA) level II or greater, decompensated heart failure~6. Previous myocardial infarction or stroke~7. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other DSM-III disorders, or any other psychiatric condition, which in the investigator's opinion will interfere significantly with study compliance~8. History of major depressive disorder or suicidality~9. Any clinically significant cardiac arrhythmia~10. Treatment with calcium channel blockers and beta blockers~11. Concomitant use of monoaminooxidase inhibitors~12. Bulimia or anorexia nervosa~13. Any agent used for weight loss in the past 3 months~14. Untreated hypo- or hyperthyroidism~15. Clinically significant liver (\>3x ULN (Upper Limit of Normal range)) and/or kidney impairment~16. More than 5% weight loss within the last 3 months~17. Any other clinically meaningful condition, in the opinion of the investigator, which would make participation potentially unsafe~18. Contraindications to administration of metoprolol per current Summary of Product Characteristics

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Tesofensine/Metoprolol (Type: EXPERIMENTAL): Tesofensine + metoprolol administered once a day, in the morning with a meal
- Tesofensine/Metoprolol placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete